Sidmex Inovia offers bulk export supply of Rasbase 1.5mg Injection (RASBURICASE) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.

Documents, cold-chain shipping and tenders: see our Export FAQ.

Priority markets: Philippines, United Arab Emirates, Kenya, Egypt, Brazil. We also export worldwide, including:
Middle East: United Arab Emirates, Saudi Arabia, Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Turkey
Africa: Egypt, Algeria, Morocco, Libya, Nigeria, Ghana, Benin, Burkina Faso, Côte d'Ivoire, Gambia, Kenya, Tanzania, Rwanda, Ethiopia, Djibouti, Somalia, South Africa, Zimbabwe, Mauritius
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Singapore, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia
Latin America & Caribbean: Mexico, Brazil, Chile, Peru, Colombia, Bolivia, Dominican Republic, Bahamas, Barbados
Europe & Other: Switzerland, United Kingdom, Canada

Related products we supply: Alburel 20 gm/100 ml Injection

Rasbase 1.5mg Injection is an antihyperuricemic drug belonging to the category of uricolytic agent, containing the active ingredient Rasburicase. It is used in the treatment of acute hyperuricemia in patients receiving chemotherapy. When cancer cells break down, they can release large amounts of uric acid into the bloodstream. This can cause hyperuricemia, which can lead to kidney damage and other health problems. Also, this medicine can be used to prevent or treat hyperuricemia in patients with tumor lysis syndrome(a large number of cancer cells die within a few periods). In patients with G6PD deficiency, rasburicase can trigger hemolysis(destruction of RBC) by generating reactive oxygen species that damage red blood cells. As a result, rasburicase is generally contraindicated in patients with G6PD deficiency. If you are diagnosed with this deficiency, inform your physician before taking this medicine because you will be more likely to experience severe haemolytic anaemia or methemoglobinemia(an abnormal form of haemoglobin). Children who are undergoing chemotherapy for leukaemia, lymphoma, or solid tumor malignancies are at risk for developing hyperuricemia, which can lead to kidney damage, seizures, and other complications. This drug helps to treat hyperuricemia by rapidly reducing the levels of uric acid in the blood.It is important to closely monitor children who are receiving rasburicase for any signs of allergic reactions, hemolysis (breakdown of red blood cells), or any other side effects. Talk with your healthcare provider if you have kidney or liver disease, vision problems and lung problems. Your healthcare provider will check regular blood tests to prevent complications. Avoid consuming alcohol as it may cause dizziness. Consult your doctor before using this medication if you are pregnant or plan to have a baby. Rasbase 1.5mg Injections are unsafe to use during pregnancy as it causes harm to an unborn fetus. Your health care practitioner will conduct a pregnancy test before you start treatment with Rasbase 1.5mg Injection. Discuss with your doctor effective birth control methods and utilise them for at least two weeks following the last dose.